Buy Rating Affirmed: Jasper Therapeutics' Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment Market

TipRanksApr 25 10:55

Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) Market Cap Dropped US$88m Last Week; Individual Investors Who Hold 36% Were Hit as Were Institutions

Key Insights The considerable ownership by individual investors in Jasper Therapeutics indicates that they collectively have a greater say in management and business strategy A total of 12 investors

Simply Wall StApr 19 18:06

Jasper Therapeutics Initiated at Outperform by Evercore ISI Group

Jasper Therapeutics Initiated at Outperform by Evercore ISI Group

Dow JonesApr 3 19:44

Evercore ISI Group Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $65

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Jasper Therapeutics with a Outperform rating and announces Price Target of $65.

Analyst UpgradesApr 3 19:34

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

PDF Version REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel an

Jasper TherapeuticsApr 2 12:00

RBC Starts Jasper Therapeutics at Outperform, Cites Market Opportunity

Seeking AlphaMar 29 04:03